ProfileGDS5678 / 1428539_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 80% 78% 79% 81% 78% 82% 83% 79% 79% 79% 80% 82% 79% 78% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.6436880
GSM967853U87-EV human glioblastoma xenograft - Control 25.4244978
GSM967854U87-EV human glioblastoma xenograft - Control 35.5383879
GSM967855U87-EV human glioblastoma xenograft - Control 45.9684281
GSM967856U87-EV human glioblastoma xenograft - Control 55.4229778
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.7256482
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.9087383
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.4906379
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.5810279
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.5926879
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.5859980
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.0106682
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.436679
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.3562778